Golf Tournament 2012

Annual Golf Tournament

 

The First Annual Sharon Leigh Cancer Organization Golf Tournament


Sharon with Kelli and Mike from Cedar-Sinai
Was an amazing success!
The fundraising effort was very successful and lots of fun was had by everyone. We can't wait until next year!

June 29, 2012 proved to be an incredibly successful fundraising event considering the fact that the tournament, held at Monarch Dunes, was a first time happening. The tournament, the committee, and sponsors were able to raise over $40,000. The purpose of the tournament is for awareness and research for early detection of Ovarian cancer.

This was our signature fundraiser benefiting Cedars Sinai ovarian research.
(Listen to Sharon discuss the golf tournament on the Dave Congalton Show by clicking here)

 

 

Photos from the golf tournament:

Booklet Cover

Welcome



Preparing

One of the Tables



What a Beautiful Day

Getting Started



Checking it Out

Riding in Style



Closest to the Hole

Having Fun



Great Form

A Few Moments to Chat



The Winners

Our souvenir cups



The Raffle

The Wine



The Drawing


(note: below is our letter about the tournament, if you missed it but would still like to donate to help fund early detection of ovarian cancer click the button to the left, or read below.) 

Dear Friend:
If you thought you could perhaps help some of the 70% of women (wives, sisters, daughters, granddaughters) currently diagnosed with ovarian cancer too late to be saved, would you do it?

Ovarian cancer is the deadliest of the gynecological cancers, causing more deaths in the U.S. each year than all other gynecological cancers combined. The five-year survival rate is over 90% and long-term prognosis is good for those women diagnosed with ovarian cancer in Stage 1.

But only 30% of women diagnosed are still in Stage 1. The Sharon Leigh Cancer Organization, Inc., a nonprofit, was created on the Central California Coast to raise research funds and spread the word about the importance of early detection for ovarian cancers.

Now you can help increase the chances that women will benefit from early detection and that research break-throughs for ovarian cancer will emerge. The Sharon Leigh Cancer Organization is establishing its first outreach effort and fundraiser. An estimated 25,000 Central Coast women will be educated about the benefits of early detection of ovarian cancer through promotion of the event. Net proceeds from the inaugural fundraiser will benefit Cedars-Sinai ovarian research. Cedars-Sinai is a national leader in research supporting early detection of women’s cancers.

The First Annual “Ovarian Cancer Benefit Golf Tournament”, hosted by the Sharon Leigh Cancer Organization, will take place Friday, June 29, 2012, at the Monarch Dunes Golf Course. We ask that you consider helping us increase the number of women diagnosed with ovarian cancer in time for effective treatment. Please consider a donation to the Sharon Leigh Cancer Organization or a sponsorship for the First Annual Ovarian Cancer Benefit Golf Tournament.

Respectfully,
Sharon Rude, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
(805) 473-8980

Tuesday, December 23, 2014
English Facebook Spanish Facebook Group English Facebook Group Twitter Ovarian Cancer Google+

Want to stay informed?

Up-to-date info on Ovarian Cancer

Like our Facebook page. Everyday we post the most recent breakthroughs and human interest stories on Ovarian Cancer.

Latest News

Information about ovarian cancer symptoms and treatments. Explore the latest medical research on ovarian cysts and ovarian cancer including including stages of the disease and new treatment options.
  • A common polymorphism can lead to a chain of events that dictates how a tumor will progress in certain types of cancer, including a form of breast cancer as well as ovarian cancer, according to new research. The research reveals a more explicit role about the symbiotic relationship humans have with the various bacteria that inhabit our body and their role during tumor progression.
  • More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other areas of the body. A new study has identified how one important gene helps cancer cells break free from the primary tumor.
  • Loss of a gene called PTEN triggers some cases of an aggressive form of ovarian cancer, called high-grade serous ovarian cancer, researchers have demonstrated. In a revolutionary approach, the researchers made the discovery by combining images from cancer samples with genetic data. They proved conclusively that loss of PTEN was commonly found only in the cancerous cells and not the 'normal' cells that help make up the tumour mass.
  • Scientists have long known the p53 protein suppresses tumors. However, a recent animal study has uncovered a complicated relationship between p53 and another protein, Rbm38, highlighting how the body calibrates protein levels.
  • A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers. Researchers behind a new study believe they may have found a molecule-based approach to halting 3q26.2's destructive nature. By manipulating a non-coding microRNA (miRNA) known as miR569 that is part of the amplicon, scientists were able to increase cell death in vitro and in vivo. MicroRNAs are short, non-coding RNA molecules that are important to controlling gene expression.
  • Finding faster and more accurate ways to test new cancer drugs is always a priority for cancer researchers. One researcher is hoping to make that happen with his innovative "tumor in a dish" method.
  • Treatment with 3TSR antiangiogenic agent is shown to regress tumors and improve effectiveness of chemotherapy in an animal model of ovarian cancer, researchers report. Like many other types of cancer, ovarian cancer obtains nutrients and oxygen by inducing the growth of new blood vessels, a process known as angiogenesis. Antiangiogenic approaches to treat cancers attempt to disrupt the balance between promoters and inhibitors of angiogenesis, either by inhibiting proangiogenic factors or by increasing antiangiogenic molecules.
  • Pelvic radiotherapy (RT) may help treat a rare form of ovarian cancer that can recur in women after surgery and chemotherapy, researchers report. The study evaluated 56 patients with ovarian clear cell adenocarcinoma (CCA), an aggressive form of ovarian cancer that is more likely to be resistant to chemotherapy and to have a poorer prognosis than other forms of this disease.
  • An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia may also prove effective against ovarian cancer – and likely other cancers as well, report researchers.